GlassScriptPhysician profile
Viji Shankar
NPI 1194911727
$3,998.18
in general payments reported to CMS, 2019-2025
29 companies · $488 in 2025
The $488 reported for 2025 was more than what 78% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $474 · 2021: $520 · 2022: $722 · 2023: $536 · 2024: $699 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $989.77 | 2021-2025 | Proclaim, Eterna |
| Scilex Pharmaceuticals INC. | $947.67 | 2019-2025 | Ztlido |
| Boston Scientific Corporation | $326.50 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Electronic Waveform Lab, INC. | $304.95 | 2019-2020 | |
| Daiichi Sankyo INC. | $246.03 | 2019 | |
| Nevro Corp. | $229.36 | 2020-2024 | Senza |
| Forte Bio-Pharma LLC | $171.20 | 2020-2023 | Prolate, Nalocet |
| Si-Bone, INC. | $121.61 | 2020-2024 | |
| Arbor Pharmaceuticals, INC. | $73.87 | 2020-2022 | |
| Grt US Holding, INC. | $65.75 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $54.46 | 2020-2023 | Xtampza |
| Vertex Pharmaceuticals Incorporated | $47.69 | 2024-2025 | |
| Pacira Therapeutics, INC. | $44.34 | 2021 | |
| Nalu Medical, INC. | $42.09 | 2021 | |
| Ibsa Pharma INC. | $40.91 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $34.49 | 2025 | Prialt |
| Fidia Pharma USA INC. | $30.98 | 2020-2023 | Hymovis, Triluron |
| Hikma Pharmaceuticals USA | $29.87 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $29.71 | 2023 | Horizant |
| Biodelivery Sciences International, INC. | $27.96 | 2019-2020 | |
| Spr Therapeutics, INC | $22.98 | 2024 | Sprint Pns System |
| Almatica Pharma LLC | $18.19 | 2021 | |
| Orthogenrx INC. | $15.85 | 2020 | |
| Radius Health, INC. | $15.10 | 2025 | Tymlos |
| Idorsia Pharmaceuticals US INC | $15.06 | 2023 | Quviviq |
| Protega Pharmaceutials INC | $14.77 | 2023 | Roxybond |
| Sentynl Therapeutics, INC. | $13.29 | 2019 | |
| Acacia Pharma INC | $12.59 | 2021 | |
| Zyla Life Sciences, INC. | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viji Shankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.